SCHEMBL1669125

SCHEMBL1669125

Clc1ccc2ccc3ncccc3c2n1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.67
MAPT P10636 5/20 0.54
KDM4E B2RXH2 4/20 0.54
CYP3A4 P08684 2/20 0.53
HSP90AA1 P07900 3/20 0.43
HTT P42858 2/20 0.43
HIF1A Q16665 2/20 0.43
CCR1 P32246 2/20 0.43
CCR8 P51685 2/20 0.43
ALOX15 P16050 2/20 0.43
GMNN O75496 1/20 0.43
TP53 P04637 1/20 0.43
MMP2 P08253 1/20 0.43
CYP2D6 P10635 1/20 0.43
MMP9 P14780 1/20 0.43
TSHR P16473 1/20 0.43
NFKB1 P19838 1/20 0.43
MMP8 P22894 1/20 0.43
THPO P40225 1/20 0.43
MTOR P42345 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Acetic Acid SCHEMBL28462134 0.89 LMNA (0.54) LMNAMAPTKDM4ECYP3A4HTT
SCHEMBL10923942 0.82 LMNA (0.53) LMNAMAPTKDM4ECYP3A4HSP90AA1
SCHEMBL310511 0.81 LMNA (0.67) LMNAMAPTKDM4ECYP3A4HSP90AA1
SCHEMBL6513577 0.80 LMNA (1.00) LMNAMAPTKDM4ECYP3A4HSP90AA1
SCHEMBL8313 0.80 LMNA (1.00) LMNAMAPTKDM4ECYP3A4HSP90AA1
SCHEMBL7040605 0.80 LMNA (0.65) LMNAMAPTKDM4ECYP3A4HSP90AA1
SCHEMBL28126432 0.80 LMNA (0.65) LMNAMAPTKDM4ECYP3A4HSP90AA1
SCHEMBL18743109 0.80 LMNA (0.55) LMNAMAPTKDM4ECYP3A4HSP90AA1
SCHEMBL28007256 0.80 LMNA (0.65) LMNAMAPTKDM4ECYP3A4HSP90AA1
SCHEMBL9860875 0.79 LMNA (0.69) LMNAMAPTKDM4ECYP3A4HSP90AA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-1994027436-A1 PRESERVATIVE SYSTEMS WITH ENHANCED ANTIMICROBIAL ACTIVITY DECICCO BENEDICT T (US) 1994-12-08 WO claimed
CN-111848663-B Non-metal organic complex salt of phenanthroline and phenanthroline derivative, and preparation method and application thereof 西南大学 2022-06-10 CN disclosed
CN-111848663-A Non-metal organic complex salt of phenanthroline and phenanthroline derivative, and preparation method and application thereof 西南大学 2020-10-30 CN disclosed
US-8956738-B2 Organic element for low voltage electroluminescent devices GLOBAL OLED TECHNOLOGY LLC (US) 2015-02-17 US disclosed
US-20130180590-A1 PHENANTHROLINE COMPOUND, ELECTRON TRANSPORT MATERIAL OBTAINED FROM SAID COMPOUND, AND ORGANIC THIN-FILM SOLAR CELL COMPRISING SAID COMPOUND IDEMITSU KOSAN CO., LTD. (JP) 2013-07-18 US disclosed
EP-2599780-A1 PHENANTHROLINE COMPOUND, ELECTRON TRANSPORT MATERIAL OBTAINED FROM SAID COMPOUND, AND ORGANIC THIN-FILM PHOTOVOLTAIC CELL COMPRISING SAID COMPOUND Idemitsu Kosan Co., Ltd. (JP) 2013-06-05 EP disclosed
EP-2373650-B1 TRIPLE SUBSTITUTED PHENANTHROLINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE OR HAEMATOLOGICAL DISEASES OR CONDITIONS, OR CANCER NOSCIRA SA (ES) 2012-10-24 EP disclosed
US-8257981-B2 Lanthanide chelates and use thereof in bioanalysis SENSIENT IMAGING TECHNOLOGIES GMBH (DE) 2012-09-04 US disclosed
EP-2485892-A1 ORGANIC ELEMENT FOR LOW VOLTAGE ELECTROLUMINESCENT DEVICES Global OLED Technology LLC (US) 2012-08-15 EP disclosed
US-20110306631-A1 TRIPLE SUBSTITUTED PHENANTHROLINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE OR HAEMATOLOGICAL DISEASES OR CONDITIONS, OR CANCER NOSCIRA, S.A. (ES) 2011-12-15 US disclosed
EP-2373650-A1 TRIPLE SUBSTITUTED PHENANTHROLINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE OR HAEMATOLOGICAL DISEASES OR CONDITIONS, OR CANCER Noscira, S.A. (ES) 2011-10-12 EP disclosed
US-20110136242-A1 Lanthanide Chelates and Use Thereof in Bioanalysis SENSIENT IMAGING TECHNOLOGIES GMBH (DE) 2011-06-09 US disclosed
WO-2011044009-A1 ORGANIC ELEMENT FOR LOW VOLTAGE ELECTROLUMINESCENT DEVICES GLOBAL OLED TECHNOLOGY LLC (US) 2011-04-14 WO disclosed
WO-2010066832-A1 TRIPLE SUBSTITUTED PHENANTHROLINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE OR HAEMATOLOGICAL DISEASES OR CONDITIONS, OR CANCER NOSCIRA, S.A. (ES) 2010-06-17 WO disclosed
EP-2196466-A1 Triple substituted phenanthroline derivatives for the treatment of neurodegenerative or heamatological diseases or conditions NOSCIRA, S.A. (ES) 2010-06-16 EP disclosed
US-20100019671-A1 ORGANIC ELEMENT FOR LOW VOLTAGE ELECTROLUMINESCENT DEVICES EASTMAN KODAK COMPANY 2010-01-28 US disclosed
CN-1668616-A Charge transport compositions comprising fluorizated quinazoline derivatives DU PONT (US) 2005-09-14 CN disclosed
WO-1994027436-A1 PRESERVATIVE SYSTEMS WITH ENHANCED ANTIMICROBIAL ACTIVITY DECICCO BENEDICT T (US) 1994-12-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110306631-A1 TRIPLE SUBSTITUTED PHENANTHROLINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE OR HAEMATOLOGICAL DISEASES OR CONDITIONS, OR CANCER HTT, PFN1, PSEN1 LMNA 1060/4885MAPT 12/4885KDM4E 1171/4885
US-20110136242-A1 Lanthanide Chelates and Use Thereof in Bioanalysis LANCL2, LANCL1, SSB LMNA 2348/4885MAPT 4811/4885KDM4E 2885/4885
US-20130180590-A1 PHENANTHROLINE COMPOUND, ELECTRON TRANSPORT MATERIAL OBTAINED FROM SAID COMPOUND, AND ORGANIC THIN-FILM SOLAR CELL COMPRISING SAID COMPOUND SLC43A1, SLC7A5, SLC9A2 LMNA 1378/4885MAPT 2918/4885KDM4E 1109/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.